Generalized Anxiety Disorder Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Pfizer

Posted on
by

Generalized Anxiety Disorder Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Pfizer
The Generalized Anxiety Disorder Market size was valued approximately USD 1.54 billion in 2022 and the report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the 7MM.

DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Generalized Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Generalized Anxiety Disorder Market Forecast

 

Some of the key facts of the Generalized Anxiety Disorder Market Report: 

  • The Generalized Anxiety Disorder market size was valued approximately USD 1.54 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In March 2024, Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company dedicated to advancing traditional and innovative behavioral health treatments, congratulates Mind Medicine (“MindMed” NASDAQ: MNMD, Cboe Canada: MMED) on the encouraging results obtained from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for generalized anxiety disorder (“GAD”). The trial revealed that four weeks after a single 100-microgram dose of MM120, 48 percent of participants achieved remission, showing no clinically significant anxiety, and 65 percent displayed clinically meaningful improvement. Given the initial clinical findings from the Phase 2b trial and the considerable unmet medical need in GAD treatment, the U.S. Food & Drug Administration (“FDA”) has classified MM120 for GAD as a breakthrough therapy.
  • In February 2024, Incannex Healthcare Inc. (Nasdaq: IXHL), a prominent biotechnology company specializing in cannabinoid and psychedelic medicine, is delighted to report favorable top-line findings from its Phase 2 Psi-GAD1 clinical trial investigating psilocybin for generalized anxiety disorder (GAD). The study successfully achieved its primary objective, showing a significant clinical benefit in the psilocybin treatment group compared to the placebo group.
  • In 2022, there were 16,158,749 diagnosed prevalent cases of GAD in the 7MM overall. The United States was involved in almost 52% of these cases
  • In France, there were 373,406 severe cases of Generalized Anxiety Disorder in 2022, 515,601 moderate cases, and 267,049 light ones. According to assessments made by DelveInsight’s analysts, incidences of GAD in adults with varying degrees of severity are expected to rise in the years to come
  • Germany has the greatest frequency of Generalized Anxiety Disorder among the EU-4 nations, with an estimated 1,450,264 cases in 2022, and the number of cases is projected to continue rising by 2032
  • In Germany, there were 958,624 cases of Generalized Anxiety Disorder in females and 491,639 cases in males in 2022. DelveInsight experts’ assessments indicate that the general prevalence in both genders is likely to rise in the upcoming years
  • Key Generalized Anxiety Disorder Companies: Fabre-Kramer Pharmaceuticals, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories, Sumitomo Pharma, Eli Lilly and Company, Engrail Therapeutics INC, H. Lundbeck A/S, Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Inc., Pfizer, Bristol-Myers Squibb, and others
  • Key Generalized Anxiety Disorder Therapies: EXXUA, MM-120, Ulotaront(SEP363856), CD-008-0045, Troriluzole, Vilazodone, SEP-363856, Duloxetine, ENX-102, Escitalopram, Vortioxetine, eszopiclone, Lu AA21004, Quetiapine fumarate, Sensoril®, Pregabalin, pexacerfont, and others
  • The Generalized Anxiety Disorder epidemiology based on gender analyzed that Generalized anxiety disorder (GAD) is more prevalent in females than males
  • The Generalized Anxiety Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Anxiety Disorder pipeline products will significantly revolutionize the Generalized Anxiety Disorder market dynamics.

 

Generalized Anxiety Disorder Overview

Generalized Anxiety Disorder (GAD) is a mental health condition characterized by persistent and excessive worry or anxiety about various aspects of life, such as work, relationships, health, or daily activities. Individuals with GAD often find it challenging to control their worry, which can interfere with their ability to function normally and lead to significant distress or impairment in social, occupational, or other important areas of life.

 

Get a Free sample for the Generalized Anxiety Disorder Market Report:

https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market

 

Generalized Anxiety Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Generalized Anxiety Disorder Epidemiology Segmentation:

The Generalized Anxiety Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Generalized Anxiety Disorder
  • Prevalent Cases of Generalized Anxiety Disorder by severity
  • Gender-specific Prevalence of Generalized Anxiety Disorder
  • Diagnosed Cases of Episodic and Chronic Generalized Anxiety Disorder

 

Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ Generalized Anxiety Disorder Epidemiology Forecast

 

Generalized Anxiety Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Anxiety Disorder market or expected to get launched during the study period. The analysis covers Generalized Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Generalized Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Generalized Anxiety Disorder Therapies and Key Companies

  • EXXUA: Fabre-Kramer Pharmaceuticals
  • MM-120: Mind Med
  • Ulotaront(SEP363856): Sunovion
  • CD-008-0045: ChemRar Research
  • Troriluzole: Biohaven Pharma
  • Vilazodone: Forest Laboratories
  • SEP-363856: Sumitomo Pharma
  • Duloxetine: Eli Lilly and Company
  • ENX-102: Engrail Therapeutics INC
  • Escitalopram: H. Lundbeck A/S
  • Vortioxetine: Takeda
  • eszopiclone: Sumitomo Pharma
  • Lu AA21004: H. Lundbeck A/S
  • Quetiapine fumarate: Astrazeneca
  • Sensoril®: Natreon, Inc.
  • Pregabalin: Pfizer
  • pexacerfont: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder Treatment Market

 

Generalized Anxiety Disorder Market Strengths

  • A series of diagnostic guidelines, each building on the prior, have presented clear diagnostic criteria and led to a standardization of reporting in the field, increasing the diagnostic and treatment rate.
  • Increased diagnosis rates in various countries is directly associated with the growing geriatric population and fast-paced lifestyle among adults.
  • Research examining novel pharmacotherapies and refining psychosocial approaches for the treatment of GAD is underway and promises to provide additional treatment

 

Generalized Anxiety Disorder Market Opportunities

  • There is an urgent requirement for therapies that are safer and have rapid action.
  • Despite the significant unmet needs in the treatment, only a few players are actively involved in the therapy area, thus, the market offers opportunities to players to bring novel treatments that could shift the treatment paradigm
  • Epidemiologic studies may help in planning treatment and prevention programs, and may also help us better understand the etiology of these disorders.

 

Scope of the Generalized Anxiety Disorder Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Generalized Anxiety Disorder Companies: Fabre-Kramer Pharmaceuticals, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories, Sumitomo Pharma, Eli Lilly and Company, Engrail Therapeutics INC, H. Lundbeck A/S, Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Inc., Pfizer, Bristol-Myers Squibb, and others
  • Key Generalized Anxiety Disorder Therapies: EXXUA, MM-120, Ulotaront(SEP363856), CD-008-0045, Troriluzole, Vilazodone, SEP-363856, Duloxetine, ENX-102, Escitalopram, Vortioxetine, eszopiclone, Lu AA21004, Quetiapine fumarate, Sensoril®, Pregabalin, pexacerfont, and others
  • Generalized Anxiety Disorder Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies
  • Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder market drivers and Generalized Anxiety Disorder market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Generalized Anxiety Disorder Unmet Needs, KOL’s views, Analyst’s views, Generalized Anxiety Disorder Market Access and Reimbursement  

 

To know more about Generalized Anxiety Disorder companies working in the treatment market, visit @ Generalized Anxiety Disorder Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Generalized Anxiety Disorder Market Report Introduction

2. Executive Summary for Generalized Anxiety Disorder

3. SWOT analysis of Generalized Anxiety Disorder

4. Generalized Anxiety Disorder Patient Share (%) Overview at a Glance

5. Generalized Anxiety Disorder Market Overview at a Glance

6. Generalized Anxiety Disorder Disease Background and Overview

7. Generalized Anxiety Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Generalized Anxiety Disorder 

9. Generalized Anxiety Disorder Current Treatment and Medical Practices

10. Generalized Anxiety Disorder Unmet Needs

11. Generalized Anxiety Disorder Emerging Therapies

12. Generalized Anxiety Disorder Market Outlook

13. Country-Wise Generalized Anxiety Disorder Market Analysis (2019–2032)

14. Generalized Anxiety Disorder Market Access and Reimbursement of Therapies

15. Generalized Anxiety Disorder Market Drivers

16. Generalized Anxiety Disorder Market Barriers

17.  Generalized Anxiety Disorder Appendix

18. Generalized Anxiety Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/